Clinical trial
A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.
NCT03230097 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 29, 2017
- Completion date
- April 7, 2021
- Enrollment
- 50 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.